Advances in Medical Management of Overactive Bladder

Richelson, Elliott; Elliott, Daniel S.
June 2003
Mayo Clinic Proceedings;Jun2003, Vol. 78 Issue 6, p681
Academic Journal
Editorial. Discusses advances in the medical management of overactive bladder or urinary incontinence. Oral extended-release forms of two different muscarinic receptor antagonists, oxybutynin and tolterodine; Introduction of the transdermal oxybutynin patch; Pharmacokinetic difference between transdermal and oral preparations.


Related Articles

  • Pharmacokinetics and Metabolism of the Novel Muscarinic Receptor Agonist SNI-2011 in Rats and Dogs. Washio, Takuo; Kohsaka, Kazuhiro; Arisawa, Hirohiko; Masunaga, Hiroaki // Drug Research / Arzneimittel-Forschung;Jan2003, Vol. 53 Issue 1, p26 

    In this study, the pharmacokinetics of SNI-2011 ((�)-cis-2-methylspiro[1,3-oxathiolane-5,3'-quinuclidine]monohydro chloride hemihydrate, cevimeline, CAS 153504-70-2), a novel muscarinic acetylcholine receptor agonist developed for the treatment of Sj�gren's syndrome, in rats and dogs...

  • Botox OK for incontinence. Gustafson, Mary // McKnight's Long-Term Care News;Oct2011, Vol. 32 Issue 10, p3 

    The article reports on the approval of Botox (botulinum toxin type A) by the U.S. Food and Drug Administration (FDA) for treating incontinence in patients with neurologic conditions including spinal cord injury and overactive bladder.

  • Incontinence patch goes over-the-counter.  // FDA Consumer;Jul/Aug98, Vol. 32 Issue 4, p5 

    Reports on the approval of the over-the-counter sale of `UroMed Patch' by the United States Food and Drug Administration. Use of this patch to help women reduce leakage from stress urinary incontinence; Amount of Americans affected by urinary incontinence; Information on the patch manufactured...

  • Clinical pharmacokinetics of drugs used to treat urge incontinence. Guay, David R.P. // Clinical Pharmacokinetics;Nov2003, Vol. 42 Issue 14, p1243 

    Urge incontinence (also known as overactive bladder) is a common form of urinary incontinence, occurring alone or as a component of mixed urinary incontinence, frequently together with stress incontinence. Because of the pathophysiology of urge incontinence, anticholinergic/antispasmodic agents...

  • A benefit-risk assessment of extended-release oxybutynin. Michel, M.C.; Michel, Martin C // Drug Safety;Sep2002, Vol. 25 Issue 12, p867 

    Oxybutynin is a muscarinic receptor antagonist, which has been available for a number of years in its original immediate-release (IR) formulation. While oxybutynin IR has proven effective for the treatment of overactive bladder, its extended use can be limited by adverse effects, particularly...

  • Botulinum toxin: Cost-effective for urge incontinence. Guttman, Cheryl // Urology Times;12/1/2008, Vol. 36 Issue 15, p5 

    The article reports on the data presented by researchers from Duke University which reveals the cost-effectiveness of Botulinum toxin (Botox) for urge incontinence treatment. The data, which utilized a Markov decision analysis model, shows that Botox is a cost effective strategy for the...

  • FDA Actions.  // Neurology Alert;Jan2009 Pharmacology Watch, p2 

    The article reports on the approval of fesoterodine fumarate for the treatment of overactive bladder by the U.S. Food and Drug Administration (FDA). Manufactured by SchwartzPharma, the drug relaxes smooth muscle of the bladder reducing urinary frequency, urge to urinate, and sudden urinary...

  • New drug treats overactive bladder without drying mouth. LoBuono, Charlotte // Drug Topics;1/10/2005, Vol. 149 Issue 1, p18 

    This article reports on the approval of solifenacin for the treatment of overactive bladder with symptoms of urgency, urinary frequency, and urge urinary incontinence by the U.S. Food and Drug Administration. According to physician Peter Sand, a professor of obstetrics and gynecology and...

  • Clinical Pharmacokinetics and Pharmacodynamics of Solifenacin. Doroshyenko, Oxana; Fuhr, Uwe // Clinical Pharmacokinetics;2009, Vol. 48 Issue 5, p281 

    The succinate salt of solifenacin, a tertiary amine with anticholinergic properties, is used for symptomatic treatment of overactive bladder. Solifenacin peak plasma concentrations of 24.0 and 40.6 ng/mL are reached 3-8 hours after long-term oral administration of a 5 or 10mg solifenacin dose,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics